ESPR Q1 2017 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q1 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$41M

Net Income

-$41M

EPS (Diluted)

$-1.80

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$215M

Total Liabilities

$22M

Stockholders' Equity

$192M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$41M	-$15M	-175.9%
Net Income	-$41M	-$15M	-178.0%